Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?

Shoaib Faruqi, Sean Zhou, Joanne Thompson, Terry Robinson, Karen Watkins, Helena Cummings, Nicola Jackson, Anoop Prakash, Michael Crooks
ERJ Open Research 2019 5: 00123-2019; DOI: 10.1183/23120541.00123-2019
Shoaib Faruqi
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shoaib Faruqi
Sean Zhou
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sean Zhou
  • For correspondence: sean.zhou@doctors.org.uk
Joanne Thompson
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terry Robinson
2Harrogate and District NHS Foundation Trust, Respiratory, Harrogate, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Watkins
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helena Cummings
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Jackson
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anoop Prakash
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Crooks
1Castle Hill Hospital, Respiratory Medicine, Cottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

FENO suppression testing is practical and feasible during assessment for biologics in severe asthma. Patients with significant FENO suppression were less likely to be recommended biologics but saw similar reductions in exacerbation frequency. http://bit.ly/35oSoxP

To the Editor:

Biologic therapies are used in atopic and/or eosinophilic asthma that remains uncontrolled on optimised conventional therapy [1–4]. Nonadherence with prescribed therapy is common in severe asthma [5] and National Health Service England's commissioning guideline [6] advises adherence assessment prior to commencing biologic therapy.

Exhaled nitric oxide fraction (FENO) is a surrogate marker of eosinophilic airway inflammation that, when elevated, supports a diagnosis of asthma [7–9]. McNicholl et al. [10] studied FENO suppression during directly observed inhaled corticosteroid (DOICS) therapy in asthma patients and demonstrated that a 42% fall in FENO over 5 days indicated suboptimal ICS adherence. On this basis, FENO suppression testing has been suggested as a way to assess adherence.

We present the outcome of FENO suppression testing using DOICS in severe asthma as part of routine practice during assessment for biologic therapy.

We conducted a prospective study of FENO suppression testing during routine care in two UK severe asthma centres. Eligible patients attended between March 2017 and January 2018, and had FENO >45 ppb on two occasions, were adherent to therapy based on clinical history and met National Institute for Health and Care Excellence criteria for biologics. Patients were converted to once-daily fluticasone furoate/vilanterol 184/22 μg (Relvar Ellipta; GlaxoSmithKline, London, UK) and taught inhaler technique by a specialist nurse prior to DOICS. Daily ICS inhalation was observed in person or via live video link using secure, widely available videoconferencing applications for 8 days. FENO, seven-item Asthma Control Questionnaire (ACQ-7), blood eosinophils and spirometry were measured on day 0 and day 8 of DOICS. Day 4 FENO was also measured in one participating centre. Follow-up data on asthma management and exacerbations were collected in June 2018, and exacerbation rates annualised for the purpose of data analysis.

SPSS software (IBM, Armonk, NY, USA) was used to perform the following statistical analyses: paired t-test or Wilcoxon sign rank test for paired data; Mann–Whitney U- or independent t-test for independent data; and Fisher's exact for categorical data.

47 patients were eligible with 44 included in the analysis (two exclusions due to loss to follow-up/missing data and one excluded as they were on maintenance oral steroids).

Median (interquartile range) FENO decreased from 86 (55.5–116.5) ppb on day 0 to 56 (31.5–80.5) ppb on day 8 (p<0.01). 19 (43.2%) participants had significant FENO suppression by day 8, defined as a reduction of >42% [10]. Of the 25 patients with FENO measured on days 1, 4 and 8, 11 reached >42% FENO suppression by day 8. Significant FENO suppression was seen by day 4 in five (45%) of these patients.

No significant change was observed in ACQ-7, blood eosinophils or forced expiratory volume in 1 s between days 0 and 8.

Primary care prescription pick-up data was available for 35 participants. 26 (74.3%) had a >80% pick-up rate. There was no relationship between prescription pick-up rate and FENO suppression (p=0.24).

Table 1 presents the change in outcomes after DOICS depending on FENO suppression status. Patients were followed-up for median 10 months (range 6–14 months). 22 patients were recommended for treatment with biologics (mepolizumab; n=16; omalizumab, n=6) with 17 patients taking biologics at the time of follow-up (mepolizumab, n=11; omalizumab, n=6). The median time to biologic initiation following DOICS was 2 months (range 0–8 months). For those receiving biologics, the median treatment duration during follow-up was 10 months (range 5–17 months).

View this table:
  • View inline
  • View popup
TABLE 1

Change in outcomes after directly observed inhaled corticosteroid (DOICS) therapy depending on exhaled nitric oxide fraction (FENO) suppression status

Exacerbation rate significantly reduced following DOICS compared to the year before (average decrease of 3.76 exacerbations per year, p<0.01). There was no difference in exacerbation rate reduction in those that went onto biologics compared with those that did not (p=0.14).

This is the first prospective study of FENO suppression testing during routine assessment for biologic therapy in asthma. Overall, FENO significantly reduced during DOICS. Individuals with significant FENO suppression were younger on average and were significantly less likely to be recommended biologics. Despite this, they experienced a similar reduction in exacerbations to those that did not suppress and were more likely to be recommended for biologics. Although this real-world study is not designed or powered to detect small differences in exacerbation rate, our findings suggest that the majority of patients that achieve FENO suppression during DOICS can improve their asthma control without the need for biologic therapy.

A number of patients recommended for biologic treatment did not receive a biologic during follow-up. This was either due to patient choice or failure to attend their appointment for biologic initiation. As a result, although the proportion of patients receiving a biologic was higher in the non-FENO suppressor group, this did not reach statistical significance.

All participants received inhaler technique training and adherence advice during routine care. However, despite participants self-reporting good adherence, nearly half had significant FENO suppression. Sustained improvement in adherence is likely responsible for the reduction in exacerbations in those not commencing biologics. This may be due to positive behavioural feedback provided by FENO suppression. A proportion of patients opted to remain on once-daily Relvar Ellipta following DOICS, which may also have impacted adherence.

There was no significant relationship between prescription pick-up rate assessed by reviewing primary care records and FENO suppression response. This suggests that in our cohort, having a high prescription pick-up rate does not indicate adherence as defined by FENO suppression testing. Although FENO suppression identified a cohort of patients that experienced clinical improvement without biologics, one fifth of FENO suppressors did require biologic therapy due to continued exacerbations. Adherence assessment is complex and we feel that FENO suppression alone should not preclude treatment with biologics [11]. Newer technologies, including digital inhaler devices [12], may enhance adherence assessment and enable FENO suppression testing to be undertaken remotely.

McNicholl et al. [10] demonstrated that a FENO reduction of >42% on day 5 was consistent with suboptimal ICS adherence. The FENO suppression testing protocol used in the severe asthma centres in this study undertook DOICS over 8 days with a subgroup undergoing FENO measurement on day 4. This method appears useful for identifying a cohort of patients in whom biologic therapy is likely to be required (nonsuppressors) and those where it may not (suppressors). It is noteworthy that almost half of patients that achieved significant FENO suppression by day 8 had suppressed by day 4. In these patients, DOICS could be stopped early, reducing the burden on the clinical team. Those that fail to suppress by day 4 should continue with DOICS for 8 days. It is unclear if longer periods of DOICS would cause FENO suppression in additional patients.

This is a real-world, study and the relatively small sample size and observational nature limit its generalisability. However, it is currently the largest prospective patient cohort in which the relationship between FENO suppression testing with DOICS and subsequent asthma management is examined in asthmatics otherwise meeting criteria for biologic therapy.

FENO suppression testing using DOICS is practical and feasible during assessment for biologic therapy in severe asthmatics. There is a clear relationship between FENO suppression and subsequent recommendation for biologic treatment. This supports a role for FENO suppression testing in clinical practice, with potential to prevent the need for biologics in a cohort of otherwise eligible patients.

Footnotes

  • Conflict of interest: S. Faruqi has nothing to disclose.

  • Conflict of interest: S. Zhou has nothing to disclose.

  • Conflict of interest: J. Thompson has nothing to disclose.

  • Conflict of interest: T. Robinson has nothing to disclose.

  • Conflict of interest: K. Watkins has nothing to disclose.

  • Conflict of interest: H. Cummings has nothing to disclose.

  • Conflict of interest: N. Jackson has nothing to disclose.

  • Conflict of interest: A. Prakash has nothing to disclose.

  • Conflict of interest: M. Crooks has nothing to disclose.

  • Received May 19, 2019.
  • Accepted October 3, 2019.
  • Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Ortega HG,
    2. Liu MC,
    3. Pavord ID, et al.
    Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371: 1198–1207. doi:10.1056/NEJMoa1403290
    OpenUrlCrossRefPubMed
    1. Normansell R,
    2. Walker S,
    3. Milan SJ, et al.
    Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.
    OpenUrlPubMed
    1. Bleecker ER,
    2. FitzGerald JM,
    3. Chanez P, et al.
    Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–2127. doi:10.1016/S0140-6736(16)31324-1
    OpenUrl
  2. ↵
    1. Bjermer L,
    2. Lemiere C,
    3. Maspero J, et al.
    Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150: 789–798. doi:10.1016/j.chest.2016.03.032
    OpenUrl
  3. ↵
    1. Makela MJ,
    2. Backer V,
    3. Hedegaard M, et al.
    Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013; 107: 1481–1490. doi:10.1016/j.rmed.2013.04.005
    OpenUrlCrossRefPubMed
  4. ↵
    NHS England. Specialised Respiratory Services (adult) – Severe Asthma. www.england.nhs.uk/publication/specialised-respiratory-services-adult-severe-asthma/. Date last updated: 2017. Date last accessed: 29 May 2018.
  5. ↵
    British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. www.brit-thoracic.org.uk/standards-of-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/. Date last updated: 2016. Date last accessed: 29 May 2018.
  6. National Institute of Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management. www.nice.org.uk/guidance/ng80. Date last updated: 2017.
  7. ↵
    1. Coumou H,
    2. Bel EH
    . Improving the diagnosis of eosinophilic asthma. Expert Rev Respir Med 2016; 10: 1093–1103. doi:10.1080/17476348.2017.1236688
    OpenUrl
  8. ↵
    1. McNicholl DM,
    2. Stevenson M,
    3. McGarvey LP, et al.
    The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186: 1102–1108. doi:10.1164/rccm.201204-0587OC
    OpenUrlCrossRefPubMed
  9. ↵
    1. Green RH,
    2. Shaw D
    . Strict adherence rules to obtain monoclonal therapy might cost lives. Lancet Respir Med 2017; 5: 678–679. doi:10.1016/S2213-2600(17)30238-2
    OpenUrl
  10. ↵
    1. Gaga M,
    2. Samitas K,
    3. Zervas E
    . Inhaler adherence in severe asthma: is there an electronic solution? Eur Respir J 2018; 51: 1702219. doi:10.1183/13993003.02219-2017
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Vol 5 Issue 4 Table of Contents
ERJ Open Research: 5 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
Shoaib Faruqi, Sean Zhou, Joanne Thompson, Terry Robinson, Karen Watkins, Helena Cummings, Nicola Jackson, Anoop Prakash, Michael Crooks
ERJ Open Research Oct 2019, 5 (4) 00123-2019; DOI: 10.1183/23120541.00123-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?
Shoaib Faruqi, Sean Zhou, Joanne Thompson, Terry Robinson, Karen Watkins, Helena Cummings, Nicola Jackson, Anoop Prakash, Michael Crooks
ERJ Open Research Oct 2019, 5 (4) 00123-2019; DOI: 10.1183/23120541.00123-2019
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • rs2070600 SNP regulates AGER splicing and sputum sRAGE
  • Procoagulant microparticles and COVID-19
  • Cancer referral and interventional pulmonology during COVID-19
Show more Original research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society